Bimatoprost

證據等級: L5

預測適應症: 10 個

Bimatoprost: From Glaucoma / Eyelash Hypotrichosis to Malformation Syndrome with Odontal and/or Periodontal Component

One-Sentence Summary

Bimatoprost is a prostaglandin FP receptor agonist (PGF2α analogue) internationally established for treating elevated intraocular pressure in glaucoma (Lumigan) and eyelash hypotrichosis (Latisse), though it holds no marketing authorisation in Denmark. The TxGNN model predicts it may be effective for Malformation Syndrome with Odontal and/or Periodontal Component, with a prediction score of 99.9974%. However, no clinical trials and no bimatoprost-specific publications directly support this direction — the 20 retrieved publications are general periodontitis background literature, not studies investigating bimatoprost for this rare congenital syndrome, placing this prediction at evidence level L5.

Quick Overview

Item	Content
Original Indication	Not registered in Denmark; internationally approved for glaucoma / ocular hypertension and eyelash hypotrichosis
Predicted New Indication	Malformation syndrome with odontal and/or periodontal component
TxGNN Prediction Score	99.9974%
Evidence Level	L5
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the Evidence Pack. Based on established pharmacology, Bimatoprost is a synthetic prostaglandin F2α (PGF2α) analogue that acts as a selective agonist at the FP prostaglandin receptor (PTGFR). In the eye, it lowers intraocular pressure by enhancing uveoscleral and trabecular aqueous outflow from the ciliary body. In hair follicles, it prolongs the anagen (active growth) phase by activating FP and EP3 receptors, a mechanism that underlies its FDA-approved use for eyelash hypotrichosis (Latisse, 2008).

The predicted indication — malformation syndrome with odontal and/or periodontal component — refers to a heterogeneous group of rare congenital syndromes characterised by developmental abnormalities in tooth structure and periodontal tissue formation. This is pathophysiologically distinct from the drug’s known mechanism: bimatoprost acts on the prostaglandin FP receptor in adult ciliary body and hair follicle tissue, not on the embryological signalling pathways (e.g., WNT, BMP, SHH) that govern odontogenesis or periodontal ligament morphogenesis. While prostaglandin E2 (PGE2) is elevated in acquired inflammatory periodontitis, the PGF2α pathway has very limited documented involvement in the bone destruction or soft-tissue pathology of inflammatory periodontal disease — and still less in the congenital developmental variants predicted here.

The extremely high TxGNN knowledge graph score (99.9974%) most plausibly reflects the topological proximity of “periodontal tissue – prostaglandin – inflammation” nodes in the knowledge graph rather than a genuine therapeutic relationship. The mechanistic bridge between bimatoprost and this congenital syndrome is absent, and this prediction should be treated with significant caution.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Important caveat: The 20 retrieved publications are general periodontitis and periodontal disease literature. None of these papers directly investigate bimatoprost for malformation syndrome with odontal/periodontal component. They were retrieved based on the periodontal disease search term and constitute background context only — they do not constitute supportive evidence for this repurposing candidate.

PMID	Year	Type	Journal	Key Findings
35688447	2022	Clinical Guideline	J Clin Periodontol	EFP S3-level evidence-based clinical practice guideline for treatment of stage IV periodontitis, covering severity, complexity and functional sequelae
35420698	2022	Cochrane Systematic Review	Cochrane Database Syst Rev	Periodontal treatment modestly improves HbA1c in diabetes mellitus; bidirectional relationship confirmed between glycaemic control and periodontitis
29291254	2018	Cochrane Systematic Review	Cochrane Database Syst Rev	Supportive periodontal therapy (SPT) reduces probability of re-infection and disease progression following active periodontal treatment
38362600	2024	Clinical Observational	J Dental Research	Stage III/IV periodontitis associated with gut microbial dysbiosis; periodontal treatment partially restores both oral and gut microbiota composition
38907216	2024	Preclinical / Basic Research	J Nanobiotechnology	Biomaterial-mediated macrophage immunotherapy proposed as novel direction in periodontitis treatment; highlights role of immune dysregulation
37435999	2023	Narrative Review	Periodontology 2000	Complications and treatment errors in regenerative periodontal surgery for intrabony and furcation defects
36883660	2023	Basic Science Review	J Dental Research	Gingival fibroblasts act as sentinel innate immune cells, modulating inflammatory response to oral pathogens in periodontitis pathogenesis
29193334	2018	Comparative Clinical Study	Periodontology 2000	Key structural differences between peri-implant and natural periodontal soft tissues; parallel collagen fibre orientation around implants differs from natural tooth attachment
22057194	2012	Review	Diabetologia	Diabetes increases susceptibility to periodontitis approximately threefold; bidirectional relationship demonstrated across multiple epidemiological datasets
12010523	2002	Evidence-based Review	J Clin Periodontol	Scaling and root planing (SRP) remains the gold standard for non-surgical treatment of chronic periodontitis, with consistent clinical outcomes across instrumentation types

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. Full safety data (key warnings and contraindications) were not available in this Evidence Pack and represent a blocking data gap that must be resolved before any clinical evaluation can proceed.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite an extremely high TxGNN knowledge graph score (99.9974%), the predicted indication — malformation syndrome with odontal and/or periodontal component — is a rare congenital developmental disorder with no mechanistic connection to bimatoprost’s prostaglandin FP receptor pharmacology. No clinical trials and no bimatoprost-specific publications exist for this indication. The evidence level is L5 (model prediction only), and the high prediction score is almost certainly a topological artefact of the knowledge graph rather than a clinically actionable signal.

⚠️ Additional safety flag — Rank 7–8 (Ambras-type Hypertrichosis Universalis Congenita): A negative mechanism alert has been identified among the top 10 predictions. Bimatoprost’s well-documented side effect profile includes hypertrichosis (excess hair growth), as explicitly listed in the Latisse prescribing information. Applying bimatoprost to treat Ambras-type congenital hypertrichosis — a condition of pathological excess hair growth — would be mechanistically contradictory and carries a concrete risk of exacerbating the condition. This prediction should be considered a knowledge graph false positive with a clinical safety concern.

To proceed with any repurposing evaluation, the following is needed:

Resolve the blocking data gap: Obtain SmPC warnings and contraindications from the official source before any safety assessment can proceed
Retrieve complete MOA data: Query DrugBank API for full mechanism of action, pharmacodynamic targets, and toxicity profile
Redirect focus to biologically plausible candidates: Hypotrichosis simplex of the scalp (Rank 9–10) is the most scientifically justified prediction in this pack — bimatoprost’s FDA-approved eyelash indication and its known FP/EP3-mediated anagen prolongation provide a direct mechanistic analogy to scalp hair follicle biology. Exploratory Phase 1/2 data for androgenetic alopecia exists in the broader literature and warrants dedicated evidence collection
Conduct a targeted literature search: Re-run PubMed and ClinicalTrials.gov searches specifically linking “bimatoprost” to the individual predicted indications, rather than broad periodontal disease terms, to verify whether the current zero-hit results reflect genuine evidence absence or collector coverage limitations
Assess route of administration feasibility: A topical formulation strategy would be required for the scalp hypotrichosis indication; Denmark market entry requirements with the Danish Medicines Agency (Lægemiddelstyrelsen) should be evaluated separately

This report is for research reference purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any therapeutic application. Prepared: 2026-04-04.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.